Amicus Therapeutics

Yahoo Finance • 7 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

Target initiated, Nike upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Out... Full story

Yahoo Finance • 18 days ago

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) st... Full story

Yahoo Finance • 28 days ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcar... Full story

Yahoo Finance • 2 months ago

Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading

Amicus Therapeutics Inc (NASDAQ:FOLD [https://www.chartmill.com/stock/quote/FOLD]) reported second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that exceeded analyst expectations. The company's performanc... Full story

Yahoo Finance • 2 months ago

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Co... Full story

Yahoo Finance • 2 months ago

Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Amicus Therapeutics (NASDAQ:FOLD [https://seekingalpha.com/symbol/FOLD]) traded higher on Thursday after Morgan Stanley upgraded the stock, citing a favorable setup for... Full story

Yahoo Finance • 2 months ago

Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength

Investing.com - Morgan Stanley has upgraded Amicus Therapeutics (NASDAQ:FOLD) from Equalweight to Overweight with a price target of $12.00, citing the company’s strong intellectual property position ahead of summary judgment with Aurobin... Full story

Yahoo Finance • 2 months ago

Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On June 25, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that it received approval for Pombiliti (cipaglucosidase alfa) +... Full story

Yahoo Finance • 3 months ago

TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 1, analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD), keeping the price target at $2... Full story

Yahoo Finance • 3 months ago

Amicus Therapeutics stock hits 52-week low at $5.55

Amicus Therapeutics (NASDAQ:FOLD) stock recently reached a 52-week low, touching $5.55, with InvestingPro data showing the stock is currently trading at $5.59, slightly above its 52-week low. Despite the current price weakness, the compan... Full story

Yahoo Finance • 3 months ago

Japan approves Amicus Therapeutics' treatment for late-onset Pompe disease

TOKYO/PRINCETON - Japan’s Ministry of Health, Labour and Welfare has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD), Amicus Therapeutics (NASDAQ:FOLD... Full story

Yahoo Finance • 3 months ago

Sangamo rises after trial data for Fabry disease therapy

[Book with diagnosis Fabry disease and pills. Medical concept.] designer491 Shares of Sangamo Therapeutics (NASDAQ:SGMO [https://seekingalpha.com/symbol/SGMO]) traded higher in the premarket on Tuesday after the company announced positive... Full story

Yahoo Finance • 4 months ago

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + mig... Full story

Yahoo Finance • 4 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare C... Full story

Yahoo Finance • 4 months ago

Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now?

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low priced biotech stocks to buy now. Is... Full story

Yahoo Finance • 5 months ago

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies... Full story

Yahoo Finance • 5 months ago

Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other Guru stocks to invest in. Wal... Full story

Yahoo Finance • 5 months ago

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial res... Full story

Yahoo Finance • 6 months ago

Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?

We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low cost stocks to buy accord... Full story